Attached files
| file | filename |
|---|---|
| EX-23.1 - EX-23.1 - Cerevel Therapeutics Holdings, Inc. | d87562dex231.htm |
| EX-21.1 - EX-21.1 - Cerevel Therapeutics Holdings, Inc. | d87562dex211.htm |
| EX-5.1 - EX-5.1 - Cerevel Therapeutics Holdings, Inc. | d87562dex51.htm |
| S-1 - S-1 - Cerevel Therapeutics Holdings, Inc. | d87562ds1.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts” and to the use of our report dated April 10, 2020, with respect to the consolidated financial statements of Cerevel Therapeutics, Inc. included in the Registration Statement (Form S-1) and related Prospectus of Cerevel Therapeutics Holdings, Inc. for the registration of 42,437,330 shares of its common stock and 166,333 warrants to purchase shares of common stock.
/s/ Ernst & Young LLP
Boston, Massachusetts
November 25, 2020